However, depletion of B cells by anti-CD20 antibodies in melanoma patients decreases tumor-associated inflammation and CD8+ T cell numbers and CD138+ plasmablast-like cells increase T cell activation in response to anti-PD-1 blockade in vitro. This evidence concerns the gene CD8A and neoplasm.